The content on this site is intended for healthcare professionals only
Prof Eileen O'Reilly speaks to ecancer about the phase II AMPLIFY-7P trial.
This trial evaluates camupepimut (ELI-002 7P), an investigational immunotherapy targeting mutant KRAS, in patients with resected stage I–III KRAS-mutated pancreatic ductal adenocarcinoma (PDAC).
Prof O'Reilly says that although the primary disease-free survival (DFS) endpoint was not met, camupepimut showed a numerical advantage in 6-month DFS compared with observation (75.7% versus 61.7%).
Patients with mutant KRAS-specific T-cell responses also had significantly longer DFS.
The findings highlight the potential role of targeted immunotherapy in reducing recurrence risk following curative-intent treatment, warranting further investigation.
Sacituzumab govitecan combination shows promising activity in first line metastatic urothelial cancer
Tarlatamab's role in SCLC
Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC
Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC
Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer
Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer
Adjuvant pembrolizumab fails to improve recurrence-free survival after curative therapy in hepatocellular carcinoma
Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC
